BCL2L1 and ovarian carcinoma: When further analyzed in Bcl-xL+ group, Beclin 1 was evaluated as well an encouraging prognostic predictor for ovarian carcinoma patients survival (AUC = 0.675, P<0.0001, Figure 4B).